Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
PaperCitations, authors & open-access status
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 439 citations, 2015 year and bronze oa status.
439
Citations
2015
Year
bronze
OA Status